A significant factor that may be overlooked by physicians when prescribing medications lies within your genetic code.
Research released on Wednesday in Science Translational Medicine indicates that nearly 25% of participants received prescriptions that could have been altered, either in terms of the drug itself or its dosage, based on their genetic information.
The investigation, spearheaded by scientists from the University of Pittsburgh, analyzed 16 genes that play a role in how individuals metabolize medications.
The DNA of 98,590 individuals from the National Institutes of Health’s All of Us Research Program was scrutinized and matched with their medical histories when possible.
Every participant exhibited at least one genetic variation relevant to their medication response, with an average of nine variations per individual. Among those with both genetic and clinical data, 24.4% had been prescribed at least one drug that, according to genetic guidelines, should have been substituted with another medication or adjusted in dosage.
Nonetheless, the research did not assess whether patients suffered side effects or if their medications were ineffective due to their genetic profiles.
Dr. Philip Empey, an associate professor at the University of Pittsburgh’s pharmacy school and the study’s senior author, stated that understanding a patient’s genetic background could help minimize the trial and error typically associated with prescribing medications.
“The more accurately we can predict the best medications and dosages from the outset, the more we can lessen that trial and error,” he remarked.

A pharmacist organizes medications at a pharmacy in Vancouver in October 2022. Genetic differences can influence how patients respond to specific medications, which may necessitate dosage adjustments or alternative prescriptions. (Darryl Dyck/The Canadian Press)
Identifying the Suitable Medication
Omeprazole and pantoprazole for acid reflux, as well as atorvastatin for cholesterol management, were among the frequently prescribed medications to participants whose genetic profiles indicated potential modifications in treatment.
Empey noted that certain genetic variations can heighten the risk of muscular complications for patients taking statins like atorvastatin, which are utilized to lower heart attack or stroke risks.
This information could assist healthcare providers in choosing alternative medications or modifying treatment plans.
“It empowers clinicians to make more informed choices, saying, ‘Perhaps not that cholesterol medication. Maybe we begin with a lower dose. There could be an upper limit on the dosage. We may need to monitor for specific side effects more closely,'” Empey explained.
In some instances, the implications can be more severe.
For instance, experts consulted by CBC News indicate that genetic testing can reveal which patients are less likely to respond effectively to clopidogrel (Plavix), a medication prescribed to prevent blood clots post-cardiac stenting, allowing for alternative treatments.

Dr. James Kennedy, who leads the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health, asserts that genetic testing aids physicians in selecting medications, yet other factors such as diet, lifestyle, and existing medications must also be taken into account. (CBC)
A Guide, Not an Assurance
Dr. James Kennedy, head of the Tanenbaum Centre for Pharmacogenetics at CAMH, expressed that the findings of the study were anticipated, although he was particularly impressed by the genetic diversity represented, especially among individuals of African descent.
Kennedy’s team has conducted genetic testing for around 11,000 patients, many of whom had previously tried two or three antidepressants without achieving satisfactory outcomes.
He noted that roughly 8 to 10 percent of individuals metabolize certain commonly prescribed antidepressants at an unusually slow rate, resulting in medication accumulation and potential side effects.
Kennedy emphasized that genetic testing is particularly beneficial for patients who have faced challenges with multiple medications.
However, he pointed out that DNA testing alone cannot predict a patient’s response to a medication. Factors such as other medications, smoking habits, and dietary choices must also be factored in.
“We present, ‘Here’s your genetic blueprint, here are some tendencies you exhibit, and now let’s discuss all the additional factors you need to consider before making a final decision,'” he remarked.
A 2023 European clinical trial referenced in the study indicated that genetic testing prior to prescribing specific medications decreased the incidence of adverse drug reactions. However, implementing routine testing in Canada presents challenges.

A researcher at the University of Calgary holds a diagnostic kit used to identify genetic variations in February 2024. While such testing could assist doctors in personalizing treatments, practical and financial hurdles have restricted its broader implementation in Canada. (Jeff McIntosh/The Canadian Press)
The Limitations of Genetic Testing in Canada
Dr. Jacob Udell, a cardiologist in Toronto, found the study impressive, particularly noting the genetic diversity of the participants. However, he pointed out that very few healthcare providers in Canada or the U.S. routinely screen patients for genetic variations affecting drug metabolism.
“It’s certainly not a priority for front-line clinicians,” he stated.
Udell explained that for many ailments, physicians can prescribe a drug, observe the patient’s reaction, and make necessary adjustments, typically without serious repercussions. This method can be more feasible than routinely screening for genetic variations.
He also questioned whether widespread testing should take precedence when Canada’s healthcare system is already struggling to deliver fundamental services.
“We are primarily focused on ensuring everyone has a family doctor,” he remarked.
In addition to the financial aspects of testing, Udell indicated that healthcare providers would need access to genetic test results and the expertise to interpret them effectively.
Empey concurred that establishing routine genetic testing would necessitate considerable investment in training, infrastructure, and new systems for sharing results among healthcare professionals.
“The scientific basis for many medications is strong. The challenge of implementation is more related to economics, processes, and education,” he stated.
For the time being, Empey advises patients to inquire with their doctors or pharmacists about the potential benefits of genetic testing and to share any relevant results.
Udell cautioned that private testing might become more prevalent among those who can afford it, “but that won’t assist those who cannot pay for testing.”
